Release Date: June 14, 2023
Expiration Date: June 14, 2024
Activity Overview
Respiratory syncytial virus (RSV) is a common cause of respiratory illness globally. In older adults, RSV is the second leading cause of significant respiratory tract infections behind influenza; 336,000 older adults are hospitalized globally due to RSV, and the infection contributes to 177,000 hospitalizations and 14,000 deaths annually in those over the age of 65 in the United States. Due to the similarity of RSV infection with other respiratory illnesses, notably influenza and COVID-19, the medical community must be prepared to prevent and manage RSV infection, particularly among high-risk groups. Preventive interventions are limited, and treatment comprises supportive care. Consequently, targeting of RSV is a high priority for vaccine and antiviral drug development, although success has been limited. Several vaccines currently under development have the potential to decrease disease burden. As RSV vaccines become available, clinicians should be equipped to provide patients with relevant information and address patient needs and questions about vaccine safety and efficacy. This activity updates clinicians about the burden of RSV infection among vulnerable populations (notably older adults), clinical manifestations and diagnosis of RSV, and investigational RSV vaccines.
This educational activity is an archive of the live satellite symposium held on April 26, 2023.
Target Audience
This educational activity is directed toward internists and internal medicine subspecialists. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in vaccinating patients against, and treating patients for, RSV also will be invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Assess the burden of illness associated with RSV in vulnerable populations
- Apply clinical findings to accurately diagnose RSV
- Evaluate the efficacy and safety of investigational vaccines to prevent RSV in vulnerable populations
- Identify strategies to promote RSV vaccine uptake upon approval
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
